Raymond Q1 FY27 Earnings Call — Analysis (NSE: RAYMOND)
Aerospace revenue jumps 40% YoY on strong execution; 10-year order book surpasses ₹5,960 Cr and aftermarket launch set for Q2 FY27.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q1FY27 Total Income ₹628 Cr ( +13% YoY ) . New guidance — precision manufacturing segment… 12-13% . New story: Aerospace multi-year demand visibility .
Results
Consolidated revenue ₹628 Cr (+13% YoY); EBITDA ₹100 Cr (+14% YoY) with margin 15.9%; Aerospace revenue ₹123 Cr (+40% YoY) while Precision Tech EBITDA surged 46% YoY to ₹61 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Total Income | ₹628 Cr | +13% | yoy · Q1FY27 · Q1FY26 |
| EBITDA | ₹100 Cr | +14% | yoy · Q1FY27 · Q1FY26 |
| EBITDA Margin | 15.9% | yoy · Q1FY27 · Q1FY26 15.7% | |
| Aerospace Revenue | ₹123 Cr | +40% | yoy · Q1FY27 · Q1FY26 |
| Aerospace EBITDA | ₹26 Cr | +25% | yoy · Q1FY27 · Q1FY26 |
| Aerospace EBITDA Margin | 21.2% | yoy · Q1FY27 · Q1FY26 23.7% | |
| Precision Technology Revenue | ₹444 Cr | +11% | yoy · Q1FY27 · Q1FY26 |
| Precision Technology EBITDA | ₹61 Cr | +46% | yoy · Q1FY27 · Q1FY26 |
| Precision Technology EBITDA Margin | 13.8% | yoy · Q1FY27 · Q1FY26 10.6% | |
| Aerospace Order Book (10-year) | ₹5,960+ Cr | point_in_time · as of June 2026 · June 2026 | |
| Net Cash Surplus | ₹129 Cr | point_in_time · as of June 2026 · June 2026 |
Guidance
Management committed to 25% FY27 aerospace revenue growth (ahead in Q1) and expects consolidated EBITDA margin momentum to sustain, supported by operating leverage and aftermarket roll-out.
What management committed to
- Raymond Limited's aerospace business will achieve at least 25% revenue growth in FY27. — 25%, FY27
- Raymond will launch [the automotive aftermarket product line] in Q2 FY27. — Q2FY27
- The [Andhra Pradesh Gudipalli greenfield facility] will commence commercial production in late 2027. — FY28
- The existing aerospace facility will exceed a revenue capacity of INR600 crores through the [Parivartan] improvement program. — exceeding INR600 crores
- Raymond's aerospace business EBITDA margin target at mature stage is ~25%. — ~25%
- In the near term, Raymond's precision manufacturing business will report EBITDA margins in the range of 12-13%. — 12-13%, near term
Key themes
Aerospace ramp, operating leverage, and diversification into aftermarket
How the narrative shifted
- Aerospace multi-year demand visibility: Management presents the 10-year order book of ₹5,960+ Cr and daily RFQ inflow as unmatched visibility, supported by qualification barriers and global OEM sourcing shifts to India.
- Operating leverage and margin expansion: Volume growth in aerospace and precision tech is unlocking operating leverage and, together with product mix improvement and cost initiatives, driving EBITDA margin expansion; R&D expensed immediately but margins to stabilize as programs mature.
- Aftermarket and brand-led diversification: The Q2 FY27 launch of an automotive aftermarket product line leverages the B2C brand heritage and Tier-1 OEM base, creating a new revenue channel with margin potential.
- Greenfield capex timed for next growth wave: The ₹1,000 Cr 5-year capex plan is on schedule; the Andhra factory and pre-launch training facility are being built to capture demand beyond existing capacity, with commercial production targeted for late 2027.
- Defence and medical adjacencies emerging: Entry into defence execution (mass production of precision defence components) and medical certification open new adjacent markets, though plans are early-stage.
- Favourable trade and macro tailwinds: UK FTA implementation, US tariff rollbacks, and China+1 dynamics are creating a highly favourable export environment for Indian engineering and aerospace suppliers.
- Input cost headwinds managed: Rising logistics, carbide tooling, and minimum wage costs are acknowledged; management offsetting via efficiency improvements and customer pass-through discussions.
Operational commentary
- Mass production of precision defence components commenced, marking entry into defence execution.
- Automotive aftermarket product line scheduled for commercial rollout in Q2 FY27, leveraging B2C brand heritage and Tier-1 OEM base.
- Andhra Pradesh greenfield facility (Gudipalli) groundwork on track, commercial production targeted late 2027; pre-launch advanced training facility being set up ahead of schedule.
- Existing aerospace facility capacity enhanced through ‘Parivartan’ improvement program, expected to exceed ₹600 Cr revenue capacity.
- Medical components certification received (August 2026), opening titanium/stainless steel medical device adjacencies.
- Aerospace R&D expenses fully expensed in quarter (no capitalisation), enabling 40% revenue growth; expected to normalise as programs mature.
- Hired former BEL senior executive to shape defence strategy; detailed defence plan to be shared in 1-2 quarters.
- Aerospace order book now presented on 10-year horizon (₹5,960+ Cr) for better visibility; active RFQ pipeline stands at ₹1,632 Cr.
Analyst Q&A
Q. Strategy and customer pipeline for the medical components business following certification
Too early to say. We just got the certificate today. So, we will come back to all of you next quarter to see what the plan is.
Q. Evaluation of inorganic opportunities and rationale for warrant issue versus earlier internal accruals commentary
We keep evaluating various opportunities across aerospace, auto components, and defence. As and when we are close to closing, we will come back to the markets. The warrants provide additional flexibility.
Q. Timeline for conversion of the active ₹1,632 Cr aerospace RFQ pipeline
RFQs are received daily; we choose based on margin and ROCE fit. There are enough RFQs to exceed growth goals, but no specific conversion timeline was provided.
Research and educational content only. Not investment advice.